In the last three months, 7 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Intellia Therapeutics and provided 12-month price targets. The average target is $71.0, accompanied by a high estimate of $120.00 and a low estimate of $54.00. A 2.35% drop is evident in the current average compared to the previous average price target of $72.71.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of Intellia Therapeutics...
Login or create a forever free account to read this news
Sign up/Log in